Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIHARIKA B METTU

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1447427737
CMS profile
916702
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$404.87

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $310.00 1
Food and Beverage $94.87 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Becton, Dickinson and Company $310.00 1
JAZZ PHARMACEUTICALS INC. $94.87 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIHARIKA B METTU

NPI 1447427737 · CMS profile ID 916702

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447427737?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447427737?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447427737?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447427737?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $404.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $94.8706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058433579 CMS
Becton, Dickinson and Company $310.0005/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023950869 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.58 2
PY2022 $144.15 1
PY2023 $404.87 2
PY2025 $118.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $412,481.43 29
PY2024 Principal investigator $438,364.30 16
PY2023 Recipient $1,900.00 1
PY2023 Principal investigator $221,978.88 12
PY2022 Recipient $940.00 1
PY2022 Principal investigator $540,890.16 21
PY2021 Principal investigator $466,508.69 60
PY2020 Principal investigator $671,262.43 162
PY2019 Principal investigator $961,160.26 152

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

152 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $590.22 12/31/2019 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 684979403
Principal investigator 1 Genentech, Inc. $2,650.00 12/16/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681098615
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488201
Principal investigator 1 Incyte Corporation $10.38 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488203
Principal investigator 1 Incyte Corporation $8.95 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488205
Principal investigator 1 Incyte Corporation $22.94 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488207
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488209
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488247
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488249
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488251
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488253
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488255
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488257
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488259
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488261
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488263
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488265
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488267
Principal investigator 1 Incyte Corporation $22.94 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488269
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488271
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488273
Principal investigator 1 Incyte Corporation $22.94 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488275
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488277
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488279
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488281
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488283
Principal investigator 1 Incyte Corporation $8.95 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488285
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488287
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488289
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488291
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488293
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488295
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488297
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488299
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488301
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488303
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488305
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488307
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488309
Principal investigator 1 Incyte Corporation $22.94 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488311
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488313
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488315
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488317
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488319
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488321
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488323
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488325
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488327
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488329
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488331
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488333
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488335
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488337
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488339
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488341
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488343
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488345
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Covered Recipient Teaching Hospital
DELL CHILDRENS MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488347
Principal investigator 1 Incyte Corporation $10.03 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507537
Principal investigator 1 Incyte Corporation $10.03 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507539
Principal investigator 1 Incyte Corporation $5.40 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507541
Principal investigator 1 Incyte Corporation $5.40 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507543
Principal investigator 1 Incyte Corporation $5.40 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507545
Principal investigator 1 Incyte Corporation $8.95 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507547
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507549
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507551
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507553
Principal investigator 1 Incyte Corporation $17.90 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507555
Principal investigator 1 Incyte Corporation $10.80 12/09/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507557
Principal investigator 1 Incyte Corporation $95.00 12/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488615
Principal investigator 1 Incyte Corporation $5.40 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507523
Principal investigator 1 Incyte Corporation $0.10 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507525
Principal investigator 1 Incyte Corporation $15.40 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507527
Principal investigator 1 Incyte Corporation $20.06 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507529
Principal investigator 1 Incyte Corporation $52.12 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507531
Principal investigator 1 Incyte Corporation $0.02 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507533
Principal investigator 1 Incyte Corporation $103.60 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507535
Principal investigator 1 Incyte Corporation $5.40 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507587
Principal investigator 1 Incyte Corporation $20.06 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507589
Principal investigator 1 Incyte Corporation $5.40 11/08/2019 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally AdvancedMetastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations FIGHT-207 No dispute reported 06/30/2026 666507591
Principal investigator 1 Incyte Corporation $95.00 11/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488609
Principal investigator 1 Incyte Corporation $1,140.00 10/27/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471491
Principal investigator 1 Genentech, Inc. $197,803.80 10/16/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681100543
Principal investigator 1 Incyte Corporation $3,448.86 10/03/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 666471489
Principal investigator 1 Incyte Corporation $95.00 10/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488607
Principal investigator 1 Incyte Corporation $750.00 09/24/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 666471437
Principal investigator 1 Incyte Corporation $5,550.00 09/24/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 666471439
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471447
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471471
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471473
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471475
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471477
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471479
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471481
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471483
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471485
Principal investigator 1 Incyte Corporation $211.00 09/04/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471487
Principal investigator 1 Incyte Corporation $95.00 09/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488605
Principal investigator 1 Incyte Corporation $8,000.00 08/15/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471441
Principal investigator 1 Incyte Corporation $1,000.00 08/15/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471443
Principal investigator 1 Incyte Corporation $800.00 08/15/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471445
Principal investigator 1 Incyte Corporation $7,182.08 08/08/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK 3475 plus INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 666510387
Principal investigator 1 Incyte Corporation $95.00 08/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488603
Principal investigator 1 Incyte Corporation $286.00 07/22/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488523
Principal investigator 1 Genentech, Inc. $429.00 07/04/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681109583
Principal investigator 1 Incyte Corporation $95.00 07/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488601
Principal investigator 1 Incyte Corporation $9,372.16 06/13/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666510339
Principal investigator 1 Incyte Corporation $7,884.80 06/13/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666510341
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488599
Principal investigator 1 Eli Lilly and Company $79.20 05/28/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN No dispute reported 06/30/2026 654293743
Principal investigator 1 Merck Sharp & Dohme Corporation $5,400.00 05/10/2019 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK-3475 INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 691299006
Principal investigator 1 Incyte Corporation $1,778.40 05/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471417
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488597
Principal investigator 1 Genentech, Inc. $1,750.00 04/11/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681080073
Principal investigator 1 Merck Sharp & Dohme Corporation $5,400.00 04/09/2019 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK-3475 INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 691298753
Principal investigator 1 Merck Sharp & Dohme Corporation $10,800.00 04/02/2019 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK-3475 INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 691298743
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488595
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,222.66 03/21/2019 Non-covered Recipient Entity
Duke Cancer Institute
Phase IIB TMB High Pan Tumor Monotherapy No dispute reported 06/30/2026 639757491
Principal investigator 1 Incyte Corporation $11,884.80 03/21/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK 3475 plus INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 666510323
Principal investigator 1 Genentech, Inc. $163,782.15 03/14/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681095567
Principal investigator 1 Incyte Corporation $117,855.72 03/14/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors No dispute reported 06/30/2026 666510321
Principal investigator 1 Merck Sharp & Dohme Corporation $5,400.00 03/13/2019 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK-3475 INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 691298749
Principal investigator 1 Incyte Corporation $2,006.10 03/12/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471399
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488613
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,744.00 02/20/2019 Non-covered Recipient Entity
Duke Cancer Center
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 684979383
Principal investigator 1 Incyte Corporation $3,355.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471291
Principal investigator 1 Incyte Corporation $2,279.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471293
Principal investigator 1 Incyte Corporation $2,229.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471395
Principal investigator 1 Incyte Corporation $2,012.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471397
Principal investigator 1 Incyte Corporation $2,279.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471407
Principal investigator 1 Incyte Corporation $2,012.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471409
Principal investigator 1 Incyte Corporation $1,830.60 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471411
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488611
Principal investigator 1 Incyte Corporation $1,750.00 01/22/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471285
Principal investigator 1 Incyte Corporation $640.00 01/22/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471287
Principal investigator 1 Incyte Corporation $500.00 01/22/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471289
Principal investigator 1 Merck Sharp & Dohme Corporation $5,400.00 01/17/2019 Non-covered Recipient Entity
DUKE CANCER INSTITUTE
A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab MK-3475 INCB Combinations in Advanced Solid Tumors No dispute reported 06/30/2026 691298745
Principal investigator 1 Genentech, Inc. $218,224.80 01/03/2019 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 681091307
Principal investigator 1 Incyte Corporation $144.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471271
Principal investigator 1 Incyte Corporation $26,694.10 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471273
Principal investigator 1 Incyte Corporation $40,519.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471275
Principal investigator 1 Incyte Corporation $32,229.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471277
Principal investigator 1 Incyte Corporation $12,222.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471279
Principal investigator 1 Incyte Corporation $402.30 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471281
Principal investigator 1 Incyte Corporation $242.80 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471283
Principal investigator 1 Incyte Corporation $144.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471295
Principal investigator 1 Incyte Corporation $144.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471297
Principal investigator 1 Incyte Corporation $144.00 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471299
Principal investigator 1 Incyte Corporation $402.30 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471301
Principal investigator 1 Incyte Corporation $402.30 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471303
Principal investigator 1 Incyte Corporation $402.30 01/02/2019 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666471305
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies No dispute reported 06/30/2026 666488593